Bilirubin Metabolism and Jaundice

Schiff's Diseases of the Liver

Volumn , Issue , 2011, Pages 120-151

  Wolkoff, Allan W ^a   Berk, Paul D ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Benign recurrent intrahepatic cholestasis; Bilirubin; Bilirubin conjugation; Crigler Najjar syndrome(s); Dubin Johnson syndrome; Gilbert syndrome; Hyperbilirubinemia; Intrahepatic cholestasis of pregnancy; Jaundice; Progressive familial intrahepatic cholestasis; Rotor syndrome

Indexed keywords

EID: 84878537587     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119950509.ch6     Document Type: Chapter

References (269)

1. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008;60:79-127.
2. McDonagh AF. The biliverdin-bilirubin antioxidant cycle of cellular protection: missing a wheel? Free Radic Biol Med 2010;49:814-20.
3. McDonagh AF. Turning green to gold. Nat Struct Biol 2001;8:198-200.
4. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 2002;99:16093-8.
5. Kapitulnik J. Bilirubin: an endogenous product of heme degradation with both cytotoxic and cytoprotective properties. Mol Pharmacol 2004;66:773-9.
6. Foresti R, Green CJ, Motterlini R. Generation of bile pigments by haem oxygenase: a refined cellular strategy in response to stressful insults. Biochem Soc Symp 2004;71:177-92.
7. Sedlak TW, Snyder SH. Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics 2004;113:1776-82.
8. McDonagh A. Bilirubin the beneficent. Pediatrics 2004;114:1741-2.
9. Maghzal GJ, Leck MC, Collinson E, Li C, Stocker R. Limited role for the bilirubin-biliverdin redox amplification cycle in the cellular antioxidant protection by biliverdin reductase. J Biol Chem 2009;284:29251-9.
10. Berk PD, Howe RB, Bloomer JR, Berlin NI. Studies on bilirubin kinetics in normal adults. J Clin Invest 1969;48:2176-90.
11. Berk PD, Blaschke TF, Scharschmidt BF, Waggoner JG, Berlin NI. A new approach to quantitation of the various sources of bilrubin in man. J Lab Clin Med 1976;87:767-80.
12. Berlin NI, Berk PD. Quantitative aspects of bilirubin metabolism for hematologists. Blood 1981;57:983-99.
13. Berk PD, Tschudy DP, Shepley LA, Waggoner JG, Berlin NI. Hematologic and biochemical studies in a case of lead poisoning. Am J Med 1970;48:137-44.
14. Schmid R, Marver HS, Hammaker L. Enhanced formation of rapidly labelled bilirubin by phenobarbital: hepatic microsomal cytochromes as a possible source. Biochem Biophys Res Commun 1966;24:319-28.
15. Schmid R. Synthesis and degradation of microsomal hemoproteins. Drug Metab Dispos 1973;1:256-8.
16. Crosby WH, Akeroyd JH. The limits of hemoglobin synthesis in hereditary hemolytic anemias. Am J Med 1952;13:273-83.
17. Lewis VW, Verwilghen RL. Dyserythropoiesis: definition, diagnosis and assessment. In: Lewis VW, Verwilghen RL, eds. Dyserythropoiesis. New York: Academic Press, 1977:3.
18. Bissell DM, Hammaker LE. Cytochrome p-450 heme and the regulation of delta-aminolevulinic acid synthetase in the liver. Arch Biochem Biophys 1976;176:103-12.
19. Mreihil K, McDonagh AF, Nakstad B, Hansen TW. Early isomerization of bilirubin in phototherapy of neonatal jaundice. Pediatr Res 2010;67:656-9.
20. Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. N Engl J Med 2008;358:920-8.
21. Fog J, Jellum E. Structure of bilirubin. Nature 1963;198:88-9.
22. Bonnett R, Davies JE, Hursthouse MB. Structure of bilirubin. Nature 1976;262:327-8.
23. Heirwegh KP, Fevery J, Meuwissen JA, et al. Recent advances in the separation and analysis of diazo-positive bile pigments. Methods Biochem Anal 1974;22:205-50.
24. Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009;15:2049-66.
25. Blanckaert N, Heirwegh KP, Compernolle F. Synthesis and separation by thin-layer chromatography of bilirubin-IX isomers. Their identification as tetrapyrroles and dipyrrolic ethyl anthranilate azo derivatives. Biochem J 1976;155:405-17.
26. Lim CK, Peters TJ. High-performance liquid chromatographic separation of the bilirubin isomers. Methods Enzymol 1986;123: 389-95.
27. McDonagh AF. Thermal and photochemical reactions of bilirubin IX-alpha. Ann NY Acad Sci 1975;244:553-69.
28. Blanckaert N, Heirwegh KP, Zaman Z. Comparison of the biliary excretion of the four isomers of bilirubin-IX in Wistar and homozygous Gunn rats. Biochem J 1977;164:229-36.
29. Lightner DA, Wooldridge TA, McDonagh AF. Configurational isomerization of bilirubin and the mechanism of jaundice phototherapy. Biochem Biophys Res Commun 1979;86:235-43.
30. McDonagh AF, Palma LA, Lightner DA. Blue light and bilirubin excretion. Science 1980;208:145-51.
31. Hauser SC, Gollan JL. Bilirubin metabolism and hyperbilirubinaemic disorders. In: Millward-Sadler GH, Wright R, Arthur MJP, eds. Wright's Liver and Biliary Disease, 3rd edn. London: WB Saunders, 1992:317-70.
32. Blanckaert N, Fevery J. Physiology and pathophysiology of bilirubin metabolism. In: Zakim D, Boyer TD, eds. Hepatology: a textbook of liver disease. Philadelphia: WB Saunders, 1990:254-302.
33. McDonagh AF. Bile pigments: bilatrienes and 5, 15-biladienes. In: Dolphin D, ed. The Porphyrins. New York: Academic Press, 1979:293-491.
34. Brodersen R. Binding of bilirubin to albumin. CRC Crit Rev Clin Lab Sci 1980;11:305-99.
35. Hahm JS, Ostrow JD, Mukerjee P, Celic L. Ionization and selfassociation of unconjugated bilirubin, determined by rapid solvent partition from chloroform, with further studies of bilirubin solubility. J Lipid Res 1992;33:1123-37.
36. Jacobsen J. Binding of bilirubin to human serum albumin - determination of the dissociation constants. FEBS Lett 1969;5:112-14.
37. Athar H, Ahmad N, Tayyab S, Qasim MA. Use of fluorescence enhancement technique to study bilirubin-albumin interaction. Int J Biol Macromol 1999;25:353-8.
38. Ahlfors CE. Measurement of plasma unbound unconjugated bilirubin. Anal Biochem 2000;279:130-5.
39. Kaplan M, Hammerman C. Understanding severe hyperbilirubinemia and preventing kernicterus: adjuncts in the interpretation of neonatal serum bilirubin. Clin Chim Acta 2005;356:9-21.
40. Ahlfors CE, Wennberg RP. Bilirubin-albumin binding and neonatal jaundice. Semin Perinatol 2004;28:334-9.
41. Ostrow JD, Pascolo L, Brites D, Tiribelli C. Molecular basis of bilirubin-induced neurotoxicity. Trends Mol Med 2004;10:65-70.
42. Cohen RS, Wong RJ, Stevenson DK. Understanding neonatal jaundice: a perspective on causation. Pediatr Neonatol 2010;51: 143-8.
43. Gordon ER, Shaffer EA, Sass-Kortsak A. Bilirubin secretion and conjujation in the Crigler-Najjar syndrome type II. Gastroenterology 1976;70:761-5.
44. Weisiger RA, Ostrow JD, Koehler RK, et al. Affinity of human serum albumin for bilirubin varies with albumin concentration and buffer composition: results of a novel ultrafiltration method. J Biol Chem 2001;276:29953-60.
45. Nerli B, Romanini D, Pico G. Structural specificity requirements in the binding of beta lactam antibiotics to human serum albumin. Chem Biol Interact 1997;104:179-202.
46. Davies BE. Displacement of bilirubin from cord serum by sulphadimethoxine, amoxycillin, clavulanic acid in combination with either amoxycillin or ticarcillin, temocillin and cloxacillin. Br J Clin Pharmacol 1985;20:345-8.
47. Shankaran S, Poland RL. The displacement of bilirubin from albumin by furosemide. J Pediatr 1977;90:642-6.
48. Berk PD, Noyer CA. Bilirubin metabolism and the hereditary hyperbilirubinemias. Semin Liver Dis 1994;14:321-2.
49. Wisse E. Ultrastructure and function of Kupffer cells and other sinusoidal cells in the liver. Med Chir Dig 1977;6:409-18.
50. Grisham JW, Nopanitaya W, Compagno J, Nagel AE. Scanning electron microscopy of normal rat liver: the surface structure of its cells and tissue components. Am J Anat 1975;144:295-321.
51. Stremmel W, Tavoloni N, Berk PD. Uptake of bilirubin by the liver. Semin Liver Dis 1983;3:1-10.
52. Sorrentino D, Stremmel W, Berk PD. The hepatocellular uptake of bilirubin: current concepts and controversies. Mol Aspects Med 1987;9:405-28.
53. Berk PD, Blaschke TF, Waggoner JG. Defective bromosulfophthalein clearance in patients with constitutional hepatic dysfunction (Gilbert's syndrome). Gastroenterology 1972;63:472-81.
54. Berk PD, Martin JF, Vierling JM, et al. Heterogeneity of Gilbert's syndrome, as manifested by abnormalities in the hepatic transport of sulfobromophthalein and indocyanine green. In: Preisig R, Bircher G, Paumgartner G, eds. The Liver: quantitative aspects of structure amd function. Proceedings of the 2nd International Gstaad Symposium. Aulendorf: Editio Cantor, 1976.
55. Gartner U, Stockert RJ, LevineWG, Wolkoff AW. Effect of nafenopin on the uptake of bilirubin and sulfobromophthalein by isolated perfused rat liver. Gastroenterology 1982;83:1163-9.
56. Berk PD, Potter BJ, Stremmel W. Role of plasma membrane ligandbinding proteins in the hepatocellular uptake of albumin-bound organic anions. Hepatology 1987;7:165-76.
57. Cui Y, Konig J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 2001;276:9626-30.
58. Wang P, Kim RB, Chowdhury JR, Wolkoff AW. The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport. J Biol Chem2003;278:20695-9.
59. Zucker SD, Goessling W, Hoppin AG. Unconjugated bilirubin exhibits spontaneous diffusion through model lipid bilayers and native hepatocyte membranes. J Biol Chem1999;274:10852-62.
60. Rigato I, Pascolo L, Fernetti C, Ostrow JD, Tiribelli C. The human multidrug-resistance-associated protein MRP1 mediates ATP-dependent transport of unconjugated bilirubin. Biochem J 2004;383:335-41.
61. Kamisako T, Kobayashi Y, Takeuchi K, et al. Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance. J Gastroenterol 2000;35:659-64.
62. Levi AJ, Gatmaitan Z, Arias IM. Two hepatic cytoplasmic protein fractions, Y and Z, and their possible role in the hepatic uptake of bilirubin, sulfobromophthalein, and other anions. J Clin Invest 1969;48:2156-67.
63. Wolkoff AW, Goresky CA, Sellin J, Gatmaitan Z, Arias IM. Role of ligandin in transfer of bilirubin from plasma into liver. Am J Physiol 1979;236:E638-48.
64. Listowsky I, Gatmaitan Z, Arias IM. Ligandin retains and albumin loses bilirubin binding capacity in liver cytosol. Proc Natl Acad Sci USA 1978;75:1213-16.
65. Jakoby WB. The glutathione S-transferases: a group of multifunctional detoxification proteins. Adv Enzymol Relat Areas Mol Biol 1978;46:383-414.
66. Sheehan D, Mantle TJ. Evidence for two forms of ligandin (YaYa dimers of glutathione S-transferase) in rat liver and kidney. Biochem J 1984;218:893-7.
67. Ritter JK, Chen F, Sheen YY, et al. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDPglucuronosyltransferase isozymes with identical carboxyl termini. J Biol Chem 1992;267:3257-61.
68. Strassburg CP, Lankisch TO, Manns MP, EhmerU. Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability. Arch Toxicol 2008;82:415-33.
69. Berk PD, Wolkoff AW. Bilirubin metabolism and the hyperbilirubinemias. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principles of Internal Medicine, 15th edn. New York: McGraw Hill, 2001:1715-20.
70. Bosma PJ, Seppen J, Goldhoorn B, et al. Bilirubin UDPglucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem1994;269:17960-4.
71. Gatmaitan ZC, Arias IM. ATP-dependent transport systems in the canalicularmembrane of the hepatocyte. Physiol Rev 1995;75:261-75.
72. Paulusma CC, Oude Elferink RP. The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. J MolMed 1997;75:420-8.
73. Nies AT, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch 2007;453:643-59.
74. Kikuchi S, Hata M, Fukumoto K, et al. Radixin deficiency causes conjugated hyperbilirubinemia with loss of Mrp2 from bile canalicular membranes. Nat Genet 2002;31:320-5.
75. Lester R, Schmid R. Intestinal absorption of bile pigments. I. The enterohepatic circulation of bilirubin in the rat. J Clin Invest 1963;42:736-46.
76. Lester R, Schmid R. Intestinal absorption of bile pigments. II. Bilirubin absorption in man. N Engl J Med 1963;269:178-82.
77. Gollan J, Hammaker L, Licko V, Schmid R. Bilirubin kinetics in intact rats and isolated perfused liver. Evidence for hepatic deconjugation of bilirubin glucuronides. J Clin Invest 1981;67:1003-15.
78. Poland RL, Odell GB. Physiologic jaundice: the enterohepatic circulation of bilirubin. N Engl J Med 1971;284:1-6.
79. Billing BH. Intestinal and renal metabolism of bilirubin including enterohepatic circulation. In: Ostrow JD, ed. Bile Pigments and Jaundice. New York: Marcel Dekker, 1986:255-69.
80. Elder G, Gray CH, Nicholson DC. Bile pigment fate in gastrointestinal tract. Semin Hematol 1972;9:71-89.
81. Moscowitz A, WeimerM, Lightner DA, Petryka ZJ, Davis E, Watson CJ. The in vitro conversion of bile pigments to the urobilinoids by arat clostridia species as comparedwith the human fecal flora. 3. Natural d-urobilin, synthetic i-urobilin, and synthetic i-urobilinogen. Biochem Med 1971;4:149-64.
82. Troxler RF, Dawber NH, Lester R. Synthesis of urobilinogen by broken cell preparations of intestinal bacteria. Gastroenterology 1968;54:568-74.
83. Bloomer JR, Berk PD, Howe RB, Waggoner JG, Berlin NI. Comparison of fecal urobilinogen excretion with bilirubin production in normal volunteers and patients with increased bilirubin production. Clin Chim Acta 1970;29:463-71.
84. Schmidt M, Puttkammer G, Eisenburg J, Stich W. Studies of human urobilinoid metabolism. II. Determination of urobilinoid concentration of human serum and urine at acute viral hepatitis. Acta Hepatogastroenterol (Stuttg) 1974;21:134-8.
85. Jones EA, Berk PD. Chemical and immunological tests in the evaluation of liver disease. In: Brown SS, Mitchell FL, Young DS, eds. Chemical Diagnosis of Disease. Amsterdam: Elsevier, 1979:525-662.
86. Lee KS, Gartner LM. Fetal bilirubin metabolism and neonatal jaundice. In: Ostrow JD, ed. Bile Pigments and Jaundice. NewYork: Marcel Dekker, 1986:373-94.
87. Schmid R, Hammaker L. Metabolism and disposition of C14-bilirubin in congenital nonhemolytic jaundice. J Clin Invest 1963;42:1720-34.
88. Blanckaert N, Fevery J, Heirwegh KP, Compernolle F. Characterization of the major diazo-positive pigments in bile of homozygous Gunn rats. Biochem J 1977;164:237-49.
89. Blaschke TF, Berk PD, Scharschmidt BF, Guyther JR, Vergalla JM, Waggoner JG. Crigler-Najjar syndrome: an unusual course with development of neurologic damage at age eighteen. Pediatr Res 1974;8:573-90.
90. Hafkamp AM, Havinga R, SinaasappelM, Verkade HJ. Effective oral treatment of unconjugated hyperbilirubinemia in Gunn rats. Hepatology 2005;41:526-34.
91. Van Der Veere CN, Jansen PL, Sinaasappel M, et al. Oral calcium phosphate: a new therapy for Crigler-Najjar disease? Gastroenterology 1997;112:455-62.
92. Hafkamp AM, Nelisse-Haak R, Sinaasappel M, Oude Elferink RP, Verkade HJ. Orlistat treatment of unconjugated hyperbilirubinemia in Crigler-Najjar disease: a randomized controlled trial. Pediatr Res 2007;62:725-30.
93. Fulop M, Sandson J, Brazeau P. Dialyzability, protein binding, and renal excretion of plasma conjugated bilirubin. J Clin Invest 1965;44:666-80.
94. Fevery J, Heirwegh K, De Groote J. Renal bilirubin clearance in liver patients. Clin Chim Acta 1967;17:63-71.
95. Monserrate IC, Garcia MDR. Alclaramiento renal de las fracciones glucuronizadas de la bilirubina en las diversas ictericias. Rev Exp Enferm Aper Dig 1975;46:1-12.
96. Ali MA, Billing BH. Renal excretion of bilirubin by the rat. Am J Physiol 1968;214:1340-5.
97. Gollan JL, Dallinger KJ, Billing BH. Excretion of conjugated bilirubin in the isolated perfused rat kidney. Clin Sci Mol Med 1978;54: 381-9.
98. Berk PD, Martin JF, Blaschke TF, Scharschmidt BF, Plotz PH. Unconjugated hyperbilirubinemia. Physiologic evaluation and experimental approaches to therapy. Ann Intern Med 1975;82:552-70.
99. Berk PD, Bloomer JR, Howe RB, Blaschke TF, Berlin NI. Bilirubin production as a measure of red cell life span. J Lab Clin Med 1972;79:364-78.
100. Jones EA, Shrager R, Bloomer JR, Berk PD, Howe RB, Berlin NI. Quantitative studies of the delivery of hepatic-synthesized bilirubin to plasma utilizing aminolevulinic acid-4-14 C and bilirubin- 3 H in man. J Clin Invest 1972;51:2450-8.
101. Berk PD, Rodkey FL, Blaschke TF, Collison HA, Waggoner JG. Comparison of plasma bilirubin turnover and carbon monoxide production in man. J Lab Clin Med 1974;83:29-37.
102. Lynch SR, Moede AL. Variation in the rate of endogenous carbon monoxide production in normal human beings. J Lab Clin Med 1972;79:85-95.
103. van den Bergh AAH, Muller P. Ueber eine direkte und eine indirekte Diazoreaktion auf Bilirubin. Biochem Z 1916;77:90.
104. Dufour DR. Evaluation of liver function and injury. In:Henry JB, ed. Clinical Diagnosis and Management by Laboratory Methods, 20th edn. Philadelphia: WB Saunders, 2001:264-80.
105. Hertz H, Dybkaer R, Lauritzen M. Direct spectrometric determination of the concentrations of (unconjugated) bilirubin and conjugated bilirubin in serum. Scand J Clin Lab Invest 1974;34:265-73.
106. Lucy A. Liquor amnii analysis in the management of the pregnancy complicated by rhesus sensitization. Am J Obstet Gynecol 1961;82:1359-70.
107. Bertini G, Rubaltelli FF. Non-invasive bilirubinometry in neonatal jaundice. Semin Neonatol 2002;7:129-33.
108. Blanckaert N, Kabra PM, Farina FA, Stafford BE, Marton LJ, Schmid R. Measurement of bilirubin and its monoconjugates and diconjugates in human serum by alkaline methanolysis and high-performance liquid chromatography. J Lab Clin Med 1980;96:198-212.
109. Gordon ER, Goresky CA. A rapid and quantitative high performance liquid chromatographic method for assaying bilirubin and its conjugates in bile. Can J Biochem 1982;60:1050-7.
110. Blanckaert N. Analysis of bilirubin and bilirubin mono- and diconjugates. Determination of their relative amounts in biological samples. Biochem J 1980;185:115-28.
111. Lauff JJ, Kasper ME, Ambrose RT. Separation of bilirubin species in serum and bile by high-performance reversed-phase liquid chromatography. J Chromatogr 1981;226:391-402.
112. Onishi S, Itoh S, Kawade N, Isobe K, Sugiyama S. An accurate and sensitive analysis by high-pressure liquid chromatography of conjugated and unconjugated bilirubin IX-alpha in various biological fluids. Biochem J 1980;185:281-4.
113. Sundberg MW, Lauff JJ, Weiss JS, et al. Estimation of unconjugated, conjugated, and "delta" bilirubin fractions in serum by use of two coated thin films. Clin Chem 1984;30:1314-17.
114. McKavanagh SM, Billing BH. The use of bond-elut for the estimation of serum bile pigments bonded covalently to albumin. Biomed Chromatogr 1987;2:62-5.
115. Bloomer JR, Berk PD, Howe RB, Berlin NI. Interpretation of plasma bilirubin levels based on studies with radioactive bilinibin. JAMA 1971;218:216-20.
116. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002;123:1367-84.
117. Blanckaert NB, Heirwegh KPM. Analysis and preparation of bilirubins and biliverdins. In: Ostrow JD, ed. Bile Pigments amd Jaundice. New York: Marcel Dekker, 1986:31-79.
118. Gambino SR, Other A, Burns W. Direct serum bilirubin and the sulfobromophthalein test in occult liver disease. JAMA 1967;201:1047-9.
119. Tarao K, Fukushima K, Endo O, Kamiyo A. The effects of acute infectious hepatitis and cirrhosis of the liver on the nonerythropoietic component of early bilirubin. J Lab Clin Med 1976;87: 240-50.
120. Samson D, Halliday D, Chanarin I. Enhancement of bilirubin clearance and hepatic haem turnover by ethanol [Letter]. Lancet 1976;2:256.
121. Robinson SH. Increased bilirubin formation from nonhemoglobin sources in rats with disorders of the liver. J Lab Clin Med 1969;73:668-76.
122. Kirshenbaum G, Shames DM, Schmid R. An expanded model of bilirubin kinetics: effect of feeding, fasting, and phenobarbital in Gilbert's syndrome. J Pharmacokinet Biopharm 1976;4:115-55.
123. Gisselbrecht C, Berk PD. Failure of phenobarbital to increase bilirubin production in the rat. Biochem Pharmacol 1974;23:2895-905.
124. Okuda H, Tavoloni N, Blaschke TF, et al. Phenobarbital does not increase early labeling of bilirubin from 4-[14C]-deltaaminolevulinic acid in man and rat. Hepatology 1991;14:1153-60.
125. Bancroft JD, Kreamer B, Gourley GR. Gilbert syndrome accelerates development of neonatal jaundice. J Pediatr 1998;132:656-60.
126. Korenblat KM, Berk PD. Hyperbilirubinemia in the setting of antiviral therapy. Clin Gastroenterol Hepatol 2005;3:303-10.
127. Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 2005;192:1381-6.
128. Kartenbeck J, Leuschner U, Mayer R, Keppler D. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 1996;23:1061-6.
129. Paulusma CC, Kool M, Bosma PJ, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1997;25:1539-42.
130. Blaschke TF, Berk PD, Rodkey FL, Scharschmidt BF, Collison HA, Waggoner JG. Drugs and the liver. I. Effects of glutethimide and phenobarbital on hepatic bilirubin clearance, plasma bilirubin turnover and carbon monoxide production in man. Biochem Pharmacol 1974;23:2795-806.
131. Crigler JF Jr, Najjar VA. Congenital familial nonhemolytic jaundice with kernicterus. Pediatrics 1952;10:169-80.
132. Childs B, Sidbury JB, Migeon CJ. Glucuronic acid conjugation by patients with familial nonhemolytic jaundice and their relatives. Pediatrics 1959;23:903-13.
133. Arias IM, Gartner LM, Cohen M, Ezzer JB, Levi AJ. Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity. Am J Med 1969;47:395-409.
134. Burchell B, Coughtrie MW, Jackson MR, Shepherd SR, Harding D, Hume R. Genetic deficiency of bilirubin glucuronidation in rats and humans. Mol Aspects Med 1987;9:429-55.
135. Bosma PJ, Chowdhury NR, Goldhoorn BG, et al. Sequence of exons and the flanking regions of human bilirubin-UDPglucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I. Hepatology 1992;15:941-7.
136. Wolkoff AW, Chowdhury JR, Gartner LA, et al. Crigler-Najjar syndrome (type I) in an adult male. Gastroenterology 1979;76:840-8.
137. Fox IJ, Chowdhury JR, Kaufman SS, et al. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med 1998;338:1422-6.
138. Ambrosino G, Varotto S, Strom SC, et al. Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1. Cell Transplant 2005;14:151-7.
139. Van Der Veere CN, Sinaasappel M, McDonagh AF, et al. Current therapy for Crigler-Najjar syndrome type 1: report of a world registry. Hepatology 1996;24:311-15.
140. Schauer R, Stangl M, Lang T, et al. Treatment of Crigler-Najjar type 1 disease: relevance of early liver transplantation. J Pediatr Surg 2003;38:1227-31.
141. Morioka D, Kasahara M, Takada Y, et al. Living donor liver transplantation for pediatric patients with inheritable metabolic disorders. Am J Transplant 2005;5:2754-63.
142. Shneider BL. Pediatric liver transplantation in metabolic disease: clinical decision making. Pediatr Transplant 2002;6:25-9.
143. Gunn CH. Hereditary acholuric jaundice in a new mutant strain of rats. J Hered 1938;29:137.
144. Schmid R, Axelrod J, Hammaker L, Swarm RL. Congenital jaundice in rats, due to a defect in glucuronide formation. J Clin Invest 1958;37:1123-30.
145. Arias IM. Chronic unconjugated hyperbilirubinemia without overt signs of hemolysis in adolescents and adults. J Clin Invest 1962;41:2233-45.
146. Jansen PL. Diagnosis and management of Crigler-Najjar syndrome. Eur J Pediatr 1999;158(Suppl 2):S89-94.
147. Yaffe SJ, Levy G, Matsuzawa T, Baliah T. Enhancement of glucuronide-conjugating capacity in a hyperbilirubinemic infant due to apparent enzyme induction by phenobarbital. N Engl J Med 1966;275:1461-6.
148. Gollan JL, Huang SN, Billing B, Sherlock S. Prolonged survival in three brothers with severe type 2 Crigler-Najjar syndrome. Ultrastructural and metabolic studies. Gastroenterology 1975;68:1543-55.
149. Holstein A, Plaschke A, Lohse P, Egberts EH. Successful photoand phenobarbital therapy during pregnancy in a woman with Crigler-Najjar syndrome type II. Scand J Gastroenterol 2005;40:1124-6.
150. Ito T, Katagiri C, Ikeno S, Takahashi H, Nagata N, Terakawa N. Phenobarbital following phototherapy for Crigler-Najjar syndrome type II with good fetal outcome: a case report. J Obstet Gynaecol Res 2001;27:33-5.
151. Servedio V, d'Apolito M, Maiorano N, et al. Spectrum of UGT1A1 mutations in Crigler-Najjar (CN) syndrome patients: identification of twelve novel alleles and genotype-phenotype correlation. Hum Mutat 2005;25:325.
152. Gilbert A, Lereboullet P. La cholamae simple familiale. Semin Med 1901;21:241.
153. Berk PD, Bloomer JR, Howe RB, Berlin NI. Constitutional hepatic dysfunction (Gilbert's syndrome). A new definition based on kinetic studies with unconjugated radiobilirubin. Am J Med 1970;49:296-305.
154. Martin JF, Vierling JM, Wolkoff AW, et al. Abnormal hepatic transport of indocyanine green in Gilbert's syndrome. Gastroenterology 1976;70:385-91.
155. Vierling JM, Berk PD, Hofmann AF, Martin JF, Wolkoff AW, Scharschmidt BF. Normal fasting-state levels of serum cholylconjugated bile acids in Gilbert's syndrome: an aid to the diagnosis. Hepatology 1982;2:340-3.
156. Bosma PJ. Inherited disorders of bilirubin metabolism. J Hepatol 2003;38:107-17.
157. Burchell B, Hume R. Molecular genetic basis of Gilbert's syndrome. J Gastroenterol Hepatol 1999;14:960-6.
158. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995;333:1171-5.
159. Berk PD, Berman MD, Blitzer BL, et al. Effect of splenectomy of hepatic bilirubin clearance in patients with hereditary spherocytosis. Implications for the diagnosis of Gilbert's syndrome. J Lab Clin Med 1981;98:37-45.
160. Takeuchi K, Kobayashi Y, Tamaki S, et al. Genetic polymorphisms of bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese patients with Crigler-Najjar syndrome or Gilbert's syndrome as well as in healthy Japanese subjects. J Gastroenterol Hepatol 2004;19:1023-8.
161. Okolicsanyi L, Fevery J, Billing B, et al. How should mild, isolated unconjugated hyperbilirubinemia be investigated? Semin Liver Dis 1983;3:36-41.
162. Kaplan M, Hammerman C. Glucose-6-phosphate dehydrogenase deficiency: a hidden risk for kernicterus. Semin Perinatol 2004;28:356-64.
163. Herschel M, Ryan M, Gelbart T, Kaplan M. Hemolysis and hyperbilirubinemia in an African American neonate heterozygous for glucose-6-phosphate dehydrogenase deficiency. J Perinatol 2002;22:577-9.
164. Nicolaidou P, Kostaridou S, Mavri A, Galla A, Kitsiou S, Stamoulakatou A. Glucose-6-phosphate dehydrogenase deficiency and Gilbert syndrome: a gene interaction underlies severe jaundice without severe hemolysis. Pediatr Hematol Oncol 2005;22:561-6.
165. Kalotychou V, Antonatou K, Tzanetea R, Terpos E, Loukopoulos D, Rombos Y. Analysis of the A(TA)(n)TAA configuration in the promoter region of the UGT1 A1 gene in Greek patients with thalassemia intermedia and sickle cell disease. Blood Cells Mol Dis 2003;31:38-42.
166. Miners JO, McKinnon RA, Mackenzie PI. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 2002;181/182:453-6.
167. Dubin IN, Johnson FB. Chronic idiopathic jaundice with unidentified pigment in liver cells; a new clinicopathologic entity with a report of 12 cases. Medicine (Baltimore) 1954;33:155-97.
168. Rotor AB, Manahan L, Florentin A. Familial nonhemolytic jaundice with direct van den Bergh reaction. Acta Med Phil 1948;5:37-49.
169. Dhumeaux D, Berthelot P. Chronic hyperbilirubinemia associated with hepatic uptake and storage impairment. A new syndrome resembling that of the mutant Southdown sheep. Gastroenterology 1975;69:988-93.
170. Sprinz H, Nelson RS. Persistent non-hemolytic hyperbilirubinemia associated with lipochrome-like pigment in liver cells: report of four cases. Ann Intern Med 1954;41:952-62.
171. Dubin IN. Chronic idiopathic jaundice; a review of fifty cases. Am J Med 1958;24:268-92.
172. Shani M, Seligsohn U, Gilon E, Sheba C, Adam A. Dubin-Johnson syndrome in Israel. I. Clinical, laboratory, and genetic aspects of 101 cases. Q J Med 1970;39:549-67.
173. Cohen L, Lewis C, Arias IM. Pregnancy, oral contraceptives, and chronic familial jaundice with predominantly conjugated hyperbilirubinemia (Dubin-Johnson syndrome). Gastroenterology 1972;62:1182-90.
174. Kondo T, Yagi R, Kuchiba K. Dubin-Johnson syndrome in a neonate {Letter]. N Engl J Med 1975;292:1028-9.
175. Nakata F, Oyanagi K, Fujiwara M, et al. Dubin-Johnson syndrome in a neonate. Eur J Pediatr 1979;132:299-301.
176. Haimi-Cohen Y, Merlob P, Marcus-Eidlits T, Amir J. Dubin-Johnson syndrome as a cause of neonatal jaundice: the importance of coproporphyrins investigation. Clin Pediatr (Phila) 1998;37:511-13.
177. Alpert S, Mosher M, Shanske A, Arias IM. Multiplicity of hepatic excretory mechanisms for organic anions. J Gen Physiol 1969;53:238-47.
178. Upson DW, Gronwall RR, Cornelius CE. Maximal hepatic excretion of bilirubin in sheep. Proc Soc Exp Biol Med 1970;134:9-12.
179. Mia AS, Gronwall RR, Cornelius CE. Unconjugated bilirubin transport in normal and mutant Corriedale sheep with Dubin-Johnson syndrome. Proc Soc Exp Biol Med 1970;135:33-7.
180. Cornelius CE, Arias IM, Osburn BI. Hepatic pigmentation with photosensitivity: a syndrome in Corriedale sheep resembling Dubin-Johnson syndrome in man. J Am Vet Med Assoc 1965;146:709-13.
181. Schulman FY, Montali RJ, Bush M, et al. Dubin-Johnson-like syndrome in golden lion tamarins (Leontopithecus rosalia rosalia). Vet Pathol 1993;30:491-8.
182. Jansen PL, Peters WH, Lamers WH. Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology 1985;5:573-9.
183. Elferink RP, Ottenhoff R, Liefting W, de Haan J, Jansen PL. Hepatobiliary transport of glutathione and glutathione conjugate in rats with hereditary hyperbilirubinemia. J Clin Invest 1989;84: 476-83.
184. Koopen NR, Wolters H, Havinga R, et al. Impaired activity of the bile canalicular organic anion transporter (Mrp2/cmoat) is not the main cause of ethinylestradiol-induced cholestasis in the rat. Hepatology 1998;27:537-45.
185. Dijkstra M, Kuipers F, Havinga R, Smit EP, Vonk RJ. Bile secretion of trace elements in rats with a congenital defect in hepatobiliary transport of glutathione. Pediatr Res 1990;28:339-43.
186. Paulusma CC, Bosma PJ, Zaman GJ, et al. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996;271:1126-8.
187. Naba H, Kuwayama C, Kakinuma C, Ohnishi S, Ogihara T. Eisai hyperbilirubinemic rat (EHBR) as an animal model affording high drug-exposure in toxicity studies on organic anions. Drug Metab Pharmacokinet 2004;19:339-51.
188. Fernandez-Checa JC, Takikawa H, Horie T, OokhtensM, Kaplowitz N. Canalicular transport of reduced glutathione in normal and mutant Eisai hyperbilirubinemic rats. J Biol Chem1992;267:1667-73.
189. Kurisu H, Kamisaka K, Koyo T, et al. Organic anion transport study in mutant rats with autosomal recessive conjugated hyperbilirubinemia. Life Sci 1991;49:1003-11.
190. Wolkoff AW, Cohen LE, Arias IM. Inheritance of the Dubin-Johnson syndrome. N Engl J Med 1973;288:113-17.
191. Butt HR, Anderson E, Foulk WT, Baggenstoss AH, Schoenfield LJ, Dickson ER. Studies of chronic idiopathic jaundice (Dubin-Johnson syndrome). II. Evaluation of a large family with the trait. Gastroenterology 1966;51:619-30.
192. Hashimoto K, Uchiumi T, Konno T, et al. Trafficking and functional defects by mutations of the ATP-binding domains in MRP2 in patients with Dubin-Johnson syndrome. Hepatology 2002;36:1236-45.
193. Cebecauerova D, Jirasek T, Budisova L, et al. Dual hereditary jaundice: simultaneous occurrence of mutations causing Gilbert's and Dubin-Johnson syndrome. Gastroenterology 2005;129:315-20.
194. Machida I, Wakusawa S, Sanae F, et al. Mutational analysis of the MRP2 gene and long-term follow-up of Dubin-Johnson syndrome in Japan. J Gastroenterol 2005;40:366-70.
195. Levanon M, Rimon S, Shani M, Ramot B, Goldberg E. Active and inactive factor VII in Dubin-Johnson syndrome with factor-VII deficiency, hereditary factor-VII deficiency and on coumadin administration. Br J Haematol 1972;23:669-77.
196. Seligsohn U, Shani M, Ramot B, Adam A, Sheba C. Dubin-Johnson syndrome in Israel. II. Association with factor-VII deficiency. Q J Med 1970;39:569-84.
197. Tamary H, Fromovich Y, Shalmon L, et al. Ala244Val is a common, probably ancient mutation causing factor VII deficiency in Moroccan and Iranian Jews. Thromb Haemost 1996;76:283-91.
198. Fromovich-Amit Y, Zivelin A, Rosenberg N, Tamary H, Landau M, Seligsohn U. Characterization of mutations causing factor VII deficiency in 61 unrelated Israeli patients. J Thromb Haemost 2004;2:1774-81.
199. Arias IM. Studies of chronic familial non-hemolytic jaundice with conjugated bilirubin in the serum with and without an unidentified pigment in the liver cells. Am J Med 1961;31:510-18.
200. Javitt NB, Kondo T, Kuchiba K. Bile acid excretion in Dubin- Johnson syndrome. Gastroenterology 1978;75:931-2.
201. Kawasaki H, Yamanishi Y, Kishimoto Y, et al. Abnormality of oral ursodeoxycholic acid tolerance test in the Dubin-Johnson syndrome. Clin Chim Acta 1981;112:13-19.
202. Mandema E, de Fraiture WH, Nieweg HO, Arends A. Familial chronic idiopathic jaundice (Dubin-Sprinz disease), with a note on bromsulphalein metabolism in this disease. Am J Med 1960;28: 42-50.203.
203. Morita M, Kihara T. Intravenous cholecystography and metabolism of meglumine iodipamide (biligrafin) in Dubin-Johnson syndrome. Diag Radiol 1971;99:5760.
204. Bar-Meir S, Baron J, Seligson U, Gottesfeld F, Levy R, Gilat T. 99mTc-HIDA cholescintigraphy in Dubin-Johnson and Rotor syndromes. Radiology 1982;142:743-6.
205. Pinos T, Constansa JM, Palacin A, Figueras C. A new diagnostic approach to the Dubin-Johnson syndrome. Am J Gastroenterol 1990;85:91-3.
206. Yoo J, Reichert DE, Kim J, Anderson CJ, Welch MJ. A potential Dubin-Johnson syndrome imaging agent: synthesis, biodistribution, and microPET imaging. Mol Imaging 2005;4:18-29.
207. Essner E, Novikoff AB. Human hepatocellular pigments and lysosomes. J Ultrastructure Res 1960;3:374-91.
208. Arias IM, Bernstein L, Toffler R, Ben-Ezzer J. Black liver disease in Corriedale sheep: Metabolism of tritiated epinephrine and incorporation of isotope into the hepatic pigment in vivo. J Clin Invest 1965;44:1026.
209. Swartz HM, Sarna T, Varma RR. On the nature and excretion of the hepatic pigment in the Dubin-Johnson syndrome. Gastroenterology 1979;76:958-64.
210. Ware AJ, Eigenbrodt EH, Shorey J, Combes B. Viral hepatitis complicating the Dubin-Johnson syndrome. Gastroenterology 1972;63:331-9.
211. Varma RR, Grainger JM, Scheuer PJ. A case of the Dubin-Johnson syndrome complicated by acute hepatitis. Gut 1970;11:817-21.
212. Schoenfield LJ, McGill DB, Hunton DB, Foulk WT, Butt HR. Studies of chronic idiopathic jaundice (Dubin-Johnson syndrome). I. Demonstration of hepatic excretory defect. Gastroenterology 1963;44:101-11.
213. Erlinger S, Dhumeaux D, Desjeux JF, Benhamou JP. Hepatic handling of unconjugated dyes in the Dubin-Johnson syndrome. Gastroenterology 1973;64:106-10.
214. Abe H, Okuda K. Biliary excretion of conjugated sulfobromophthalein (BSP) in constitutional conjugated hyperbilirubinemias. Digestion 1975;13:272-83.
215. Rodes J, Zubizarreta A, Bruguera M. Metabolism of the bromsulphalein in Dubin-Johnson syndrome. Diagnostic value of the paradoxical increase in plasma levels at BSP. Am J Dig Dis 1972;17:545-52.
216. Koskelo P, Toivonen I, Adlercreutz H. Urinary coproporphyrin isomer distribution in the Dubin-Johnson syndrome. Clin Chem 1967;13:1006-9.
217. Ben Ezzer J, Rimington C, Shani M, Seligsohn U, Sheba C, Szeinberg A. Abnormal excretion of the isomers of urinary coproporphyrin by patients with Dubin-Johnson syndrome in Israel. Clin Sci 1971;40:17-30.
218. Berk PD, Wolkoff AW, Berlin NI. Inborn errors of bilirubin metabolism. Med Clin North Am 1975;59:803-16.
219. Ben Ezzer J, Blonder J, Shani M, et al. Dubin-Johnson Syndrome. Abnormal excretion of the isomers of urinary coproporphyrin by clinically unaffected family members. Isr J Med Sci 1973;9: 1431-6.
220. Kitamura T, Alroy J, Gatmaitan Z, et al. Defective biliary excretion of epinephrine metabolites in mutant (TR-) rats: relation to the pathogenesis of black liver in the Dubin-Johnson syndrome and Corriedale sheep with an analogous excretory defect. Hepatology 1992;15:1154-9.
221. Wolf RL, Pizette M, Richman A, et al. Chronic idiopathic jaundice. A study of two afflicted families. Am J Med 1960;28:32-41.
222. Kondo T, Kuchiba K, Ohtsuka Y, Yanagisawa W, Shiomura T, Taminato T. Clinical and genetic studies on Dubin-Johnson syndrome in a cluster area in Japan. Jap J Human Genet 1974;18: 378-92.
223. Shani M, Gilon E, Ben-Ezzer J, Sheba C. Sulfobromophthalein tolerance test in patients with Dubin-Johnson syndrome and their relatives. Gastroenterology 1970;59:842-7.
224. Kondo T, Kuchiba K, Shimizu Y. Metabolic fate of exogenous deltaaminolevulinic acid in Dubin-Johnson syndrome. J Lab Clin Med 1979;94:421-8.
225. Frank M, Doss M, de Carvalho DG. Diagnostic and pathogenetic implications of urinary coproporphyrin excretion in the Dubin-Johnson syndrome. Hepatogastroenterology 1990;37: 147-51.
226. Keppler D, Konig J. Hepatic canalicular membrane 5: expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB J 1997;11:509-16.
227. Toh S, Wada M, Uchiumi T, et al. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet 1999;64:739-46.
228. Mor-Cohen R, Zivelin A, Rosenberg N, Goldberg I, Seligsohn U. A novel ancestral splicing mutation in the multidrug resistance protein 2 gene causes Dubin-Johnson syndrome in Ashkenazi Jewish patients. Hepatol Res 2005;31:104-11.
229. Konig J, Nies AT, Cui Y, Leier I, Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1999;1461:377-94.
230. Shani M, Seligsohn U, Ben Ezzer J. Effect of phenobarbital on liver functions in patients with Dubin-Johnson syndrome. Gastroenterology 1974;67:303-8.
231. Merdler C, Burke M, Shani M, Felner S, Lurie I. The effect of phenobarbital on patients with Dubin-Johnson syndrome. Digestion 1976;14:394-9.
232. Wolkoff AW, Wolpert E, Pascasio FN, Arias IM. Rotor's syndrome. A distinct inheritable pathophysiologic entity. Am J Med 1976;60:173-9.
233. Schiff L, Billing BH, Oikawa Y. Familial nonhemolytic jaundice with conjugated bilirubin in the serum. A case study. N Engl J Med 1959;260:1315-18.
234. Lima JEP, Utz E, Roisenberg I. Hereditary nonhemolytic conjugated hyperbilirubinemia without abnormal liver cell pigmentation. Am J Med 1976;40:628-33.
235. Chen YW, Lee IH, Chuang YW, Chang TT, Liu GC. Tc-99m diisopropyl-iminodiacetic acid cholescintigraphic findings in Rotor's syndrome. Kaohsiung J Med Sci 2002;18:529-32.
236. Wolpert E, Fernandez E, Lisker R, Suarez GI, Dehesa M, Robles G. Rotor syndrome, a family study. Rev Invest Clin (Mex) 1974;26:363-71.
237. Porush JG, Delman AJ, Feuer MM. Chronic idiopathic jaundice with normal liver histology. Arch Intern Med 1962;109:302-9.
238. Kawasaki H, Kimura N, Irisa T, Hirayama C. Dye clearance studies in Rotor's syndrome. Am J Gastroenterol 1979;71:380-8.
239. Fedeli G, Rapaccini GL, Anti M, et al. Impaired clearance of cholephilic anions in Rotor syndrome. Z Gastroenterol 1983;21: 228-33.
240. Shimizu Y, Naruto H, Ida S, Kohakura M. Urinary coproporphyrin isomers in Rotor's syndrome: a study of eight families. Hepatology 1981;1:173-8.
241. Aziz MA, Schwartz S, Watson CJ. Studies of coproporphyrin. VIII. Reinvestigation of the isomer distribution in jaundice and liver diseases. J Lab Clin Med 1964;63:596-604.
242. Hofmann AF. Biliary secretion and excretion in health and disease: current concepts. Ann Hepatol 2007;6:15-27.
243. Clayton RJ, Iber FL, Ruebner BH, McKusick VA. Byler disease. Fatal familial intrahepatic cholestasis in an Amish kindred. Am J Dis Child 1969;117:112-24.
244. Bull LN, van Eijk MJ, Pawlikowska L, et al. A gene encoding a Ptype ATPase mutated in two forms of hereditary cholestasis. Nat Genet 1998;18:219-24.
245. Eppens EF, van Mil SW, de Vree JM, et al. FIC1, the protein affected in two forms of hereditary cholestasis, is localized in the cholangiocyte and the canalicular membrane of the hepatocyte. J Hepatol 2001;35:436-43.
246. Ujhazy P, Ortiz D, Misra S, et al. Familial intrahepatic cholestasis 1: studies of localization and function. Hepatology 2001;34:768-75.
247. Folmer DE, Elferink RP, Paulusma CC. P4 ATPases - lipid flippases and their role in disease. Biochim Biophys Acta 2009;1791: 628-35.
248. Paulusma CC, Elferink RP, Jansen PL. Progressive familial intrahepatic cholestasis type 1. Semin Liver Dis 2010;30:117-24.
249. van der Woerd WL, van Mil SW, Stapelbroek JM, Klomp LW, van de Graaf SF, Houwen RH. Familial cholestasis: progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy. Best Pract Res Clin Gastroenterol 2010;24:541-53.
250. Strautnieks SS, Bull LN, Knisely AS, et al. A gene encoding a liverspecific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998;20:233-8.
251. Lam P, Soroka CJ, Boyer JL. The bile salt export pump: clinical and experimental aspects of genetic and acquired cholestatic liver disease. Semin Liver Dis 2010;30:125-33.
252. Deleuze JF, Jacquemin E, Dubuisson C, et al. Defect of multidrugresistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology 1996;23:904-8.
253. de Vree JM, Jacquemin E, Sturm E, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA 1998;95:282-7.
254. Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. The spectrum of liver diseases related to ABCB4 genemutations: pathophysiology and clinical aspects. Semin Liver Dis 2010;30:134-46.
255. Jacquemin E, Hermans D, Myara A, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997;25:519-23.
256. Jara P, Hierro L, Martinez-Fernandez P, et al. Recurrence of bile salt export pump deficiency after liver transplantation. N Engl J Med 2009;361:1359-67.
257. Williams R, Cartter MA, Sherlock S, Scheuer PJ, Hill KR. Idiopathic recurrent cholestasis: a study of the functional and pathological lesions in four cases. Q J Med 1964;33:387-99.
258. Summerfield JA, Scott J, Berman M, et al. Benign recurrent intrahepatic cholestasis: studies of bilirubin kinetics, bile acids, and cholangiography. Gut 1980;21:154-60.
259. van Mil SW, van der Woerd WL, van der Brugge G, et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology 2004;127:379-84.
260. Williamson C, Hems LM, Goulis DG, et al. Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group. Br J Obstet Gynaecol 2004;111:676-81.
261. Bacq Y, Sapey T, Brechot MC, Pierre F, Fignon A, Dubois F. Intrahepatic cholestasis of pregnancy: a French prospective study. Hepatology 1997;26:358-64.
262. Mays JK. The active management of intrahepatic cholestasis of pregnancy. Curr Opin Obstet Gynecol 2010;22:100-3.
263. Diaferia A, Nicastri PL, Tartagni M, Loizzi P, Iacovizzi C, Di Leo A. Ursodeoxycholic acid therapy in pregnant women with cholestasis. Int J Gynaecol Obstet 1996;52:133-40.
264. Palma J, Reyes H, Ribalta J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997;27:10228.
265. Zapata R, Sandoval L, Palma J, et al. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-year experience. Liver Int 2005;25:548-54.
266. Nicastri PL, Diaferia A, Tartagni M, Loizzi P, Fanelli M. A randomised placebo-controlled trial of ursodeoxycholic acid and Sadenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. Br J Obstet Gynaecol 1998;105:1205-7.
267. Ropponen A, Sund R, Riikonen S, Ylikorkala O, Aittomaki K. Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study. Hepatology 2006;43:723-8.
268. Berk PD, Jones EA, Howe RB, Berlin NI. Disorders of bilirubin metabolism. In: Bondy PK, Rosenberg LE, eds. Metabolic Control and Disease, 8th edn. Philadelphia: WB Saunders, 1979:1009-88.
269. Berk PD. Bilirubin metabolism and the hereditary hyperbilirubinemias. In: Berk JE, Haubrich MD, Kalser, Roth JLA, Schaffner F, eds. Bockus' Gastroenterology, Vol. 5. Philadelphia: WB Saunders, 1985:2732-97.